Search Results for “EC” – Page 571 – media

Preview — Global Pharmaceutical & Medical Device Exhibitions in February, 2018

Have you made your schedule for 2018? Take some time to consider your options and see what Ddu has planned this February!
- Source: Ddu
- 1,171
- February 2, 2018
Exhibitions & Activities medical device pharmaceutical
Final NHS nod for Janssen’s Imbruvica

Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell lymphoma (MCL), after cost regulators issued a final green light for the drug.
- Source: Pharmatimes
- 525
- February 2, 2018
MCL New Approvals NHS
NHS plans to be first to eliminate hepatitis C

NHS England has laid out plans for England to become the first country to eliminate hepatitis C, at least five years earlier than the World Health Organisation(WHO)’s target date of 2030.
- Source: pharmatimes
- 872
- February 2, 2018
hepatitis C NHS polices WHO
EMA accepts MAA for romosozumab in the treatment of osteoporosis

The EMA has accepted the Marketing Authorization Application for romosozumab in the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.
- Source: europeanpharmaceuticalreview
- 869
- February 2, 2018
Amgen EMA Evenity (romosozumab) osteoporosis romosozumab
Japanese pharma set for transformation in 2018

This year could see a transformation in the Japanese pharma market, according to a new report, with strong growth stemming from increased use of generics, biosimilars and stronger links with the global industry.
- Source: PharmaPhorum
- 930
- February 2, 2018
biosimilars CPhI Market Views pharmaceutical
Body clock disruptions occur years before memory loss in Alzheimer’s

Washington University School of Medicine sleep specialist Yo-El Ju, MD, led a research team that found circadian rhythm disruptions occur in people whose memories are intact but whose brain scans show early, preclinical evidence of Alzheimer's disease. She previously had discovered that people with clinical symptoms of Alzheimer's have disturbances in their internal body clocks that affect the sleep/wake cycle. Credit: Washington University School of Medicine.
- Source: medicalxpress
- 613
- February 1, 2018
Alzheimer's disease circadian rhythm disruptions Researches
FDA Clears UC Davis Startup’s Polymer to Aid Bone Regrowth

Molecular Matrix Inc. invented a synthetic bone void filler, Osteo-P, that can help injured bones regrow.
- Source: ODT
- 600
- February 1, 2018
bone FDA medical device
Seattle Genetics Snaps Up Cascadian in $614M Buyout Deal

The year’s merger-and-acquisition trend continues. Today, the last day of January, Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
- Source: Biospace
- 455
- February 1, 2018
Cascadian HER2 Market Views merger-and-acquisition
U.K. Startup Medopad Signs Deals with Tencent and Ping An

London-based startup accompanying U.K. Prime Minister on trade mission
- Source: Bloomberg Technology
- 559
- February 1, 2018
AI China Company Insight digital health
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million.
- Source: Prnewswire
- 599
- February 1, 2018
achondroplasia infigratinib (BGJ398) Market Views Novartis QED Therapeutics

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.